Price alert —
Sign in to get a one-time email the moment DXCM crosses your price. Free accounts included.
Sign in / create a free accountDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
DXCM last traded at $76.65, down 1.7% on the day; that's in the upper part of its 52-week range ($56.72–$79.15). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 upper, +1.21 ATR from EMA21 — no notable pattern
- · Aligned with weak uptrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · RSI hook from overbought (59)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $88.64 (fair range $36–$89); today's price leaves a +13% cushion below that estimate. The model's verdict is “Undervalued” and accounting quality screens as Strong. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 1.69 (antifragile)
- ✓ Goodwill 0% of assets (organic growth)
- ✓ Positive retained earnings
- ⚠ Receivables growing faster than revenue
Price implies ~13% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
DXCM is a $29.6 billion company, priced at 33× last year's earnings, and it moves harder than the market (beta 1.5); the stock is trading near the top of its 52-week range.
Earnings
See more →- Last reported
- 2026-04-30
- EPS (act / est)
- 0.56 / 0.47
- Surprise
- +19.0%
- Next report
- 2026-07-30
About
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to repla…